GlucaGen (glucagon for injection) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2018.
3.
Glucagon for injection [prescribing information]. Indianapolis, IN: Lilly USA; 2018.
4.
OhSHDarwicheHChoJHShupeTPetersenBE.Characterization of a novel functional protein in the pancreatic islet: islet homeostasis protein regulation of glucagon synthesis in α cells. Pancreas. 2012;41(1):22-30.
5.
DeebLCDuludeHGuzmanCB, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes. 2018;19(5):1007-1013.
6.
RickelsMRRuedyKJFosterNC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264-270.
7.
SherrJLRuedyKJFosterNC, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562.
8.
GuzmanCBDuludeHPichéC, et al. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: a randomized clinical trial. Diabetes Obes Metab. 2018;20(3):646-653.
YaleJFDuludeHEgethM, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423-432.
11.
Eli Lilly and Company. Clinical usability of intranasal glucagon in treatment of hypoglycemia. NLM Identifier: NCT02171130. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02171130. Accessed April 8, 2019.
12.
SeaquistERDuludeHZhangXM, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab. 2018;20(5):1316-1320.
13.
Eli Lilly and Company. Efficacy and safety of nasal glucagon for treatment of hypoglycemia in adults. NLM Identifier: NCT01994746. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01994746. Accessed April 8, 2019.
